Brief: Almirall, Certest Biotec Sign Deal to Develop Rare Dermatology Treatments
24/07/2026 08:59
BRIEF-Almirall, Certest Biotec Sign Deal to Develop Rare Dermatology Treatments July 24 (Reuters) - Almirall SA ALM.MC:
WITH CERTEST BIOTEC SIGNS STRATEGIC RESEARCH AND LICENSING AGREEMENT
THROUGH COLLABORATION, PARTIES TO JOINTLY DISCOVER, CLINICALLY DEVELOP TREATMENTS FOR RARE DERMATOLOGIC DISEASES
Source text: https://tinyurl.com/yez74chb
Further company coverage: ALM.MC
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Almirall
See all newsBrief: Almirall Says Phase 3B Adlong Clinical Study Show Treatment Outcomes With Up To Five Years Of Lebrikizumab
Brief: Almirall And CrystalO To Discover, Develop Novel Small Molecules In Medical Dermatology
Almirall shares rise as lower costs beat EBITDA estimates
Brief: Almirall, Certest Biotec Sign Deal to Develop Rare Dermatology Treatments
Spanish stocks - Factors to watch on July 24